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concern. Astonishingly, they miss the discussion of their
previous results showing lanthanum accumulation and
damage in rat bone [3], the awareness that the effects on
the central nervous system, gut, liver, and other tissues
have never been studied in uremia, and the fact that they
themselves included lanthanum among potential toxic el-
ements in their previous papers [4].
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Reply from the Authors
We thank Dr. Canavese et al [1] for their interest in our
work; however, we disagree that we should neglect the
potential toxicity of lanthanum (La) [2]. During the last
two decades we built up a significant experience on trace
metals and renal osteodystrophy (ROD). The present
clinical trial and experimental studies assessing the pos-
sible effects of La on bone in chronic renal failure (CRF)
were set up upon our advice. Experimental data have
been reported in abstract form at international meet-
ings while manuscripts are submitted for publication. In
these studies, we found that the impaired mineralization
in La-loaded (1000 and 2000 mg/kg/day) CRF rats re-
sulted from the combination of efficient La-phosphate
(P)-binding with reduced vitamin D levels inherent to
CRF. This is corroborated by the findings that: (1) nondi-
etary P repletion restores mineralization; (2) La-loading
to rats with normal renal function does not affect mineral-
ization despite comparable bone La levels; (3) sevelamer
(Renagel, an organic, metal-free P binder) induces a
similar mineralization defect; and (4) La does not affect
osteoblastic activity. Unpublished data further indicate
that the impaired bone mineralization after La loading
improves already after a two-week washout period, while
bone La levels had not changed.
To further examine the potential toxicity of La on bone,
a “bone biopsy–based” study was set up [1]. Here, for
the first time, paired bone biopsies (baseline vs. one-
year follow-up) were taken in dialysis patients to study
the effect of a phosphate binder (i.e., La-carbonate)
on the evolution of ROD and assess its possible accu-
mulation/toxicity in/on bone. We found that, unlike Al
(aluminium), La does not to affect the bone turn-over.
Canavase et al’s concern about the increase in plasma-
La levels in patients receiving La-carbonate is quite right,
although these levels rarely exceed 2 lg/L. In humans,
the gastrointestinal absorption of La has been predicted
to be 0.00003% [3], [i.e., 1300 to 6600 times less than
the values reported for Al (0.04%-0.2%)] [4]. They also
worry about “. . .plasma La-levels reaching a plateau after
12 weeks,” suggesting tissue accumulation in the absence
of an efficient renal function. It should be noted that in
contrast to Al, biliary excretion is the major excretion
route of La. Hence, one may expect that, once equilib-
rium between bone/tissue and plasma-La concentrations
is achieved, the element will be removed from the body
via this pathway, thus minimizing the potential for tissue
accumulation [3]. Preliminary data from ongoing experi-
mental studies showing bone-La levels stabilizing below
5 lg/g after 25 weeks of La loading (2000 mg/kg) support
this statement. The important biliary excretion of La also
implies that, in contrast to various trace metals that are
mainly excreted by the kidney, including Al, CRF patients
are not at an increased risk for accumulation of La.
Finally, we stress that we always did, and still do con-
sider all elements relevant to dialysis as potentially toxic
unless the contrary has been demonstrated. Evidence for
a nontoxic action at the level of bone after one-year treat-
ment with La-carbonate has now been presented in dial-
ysis patients.
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